Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

As the song goes, Debbie with a D and London Manchester looked like Taylor Swift in the light of the AllWays Lounge in New ...

From an anal PrEP douche to the first women-controlled HIV prevention product, here's all the new HIV prevention products ...